Navigation Links
Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies

- Combination Therapy Significantly Decreased Tumor Blood Vessel Density and Serum PSA Levels in Prostate Tumors -

LOS ANGELES and TUSTIN, Calif., April 17, 2007 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that preclinical data presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR) confirms that a mouse equivalent to Peregrine's novel monoclonal antibody bavituximab given in combination with docetaxel decreased the growth of common forms of prostate cancer significantly more than either agent alone. This increase in anti-tumor efficacy was achieved with no apparent increase in toxicity. Researchers also observed that in one tumor model, the combination significantly decreased the level of serum PSA, a biomarker for prostate cancer, and in both tumor types tested it was more effective in decreasing the density of the microvessels needed to support tumor growth and development.

"This data reaffirms the potential of bavituximab for the treatment of prostate cancer in combination with docetaxel and is particularly timely since we recently completed enrollment in our first human trial of bavituximab in combination with anti-cancer agents including docetaxel," said Steven W. King, president and CEO of Peregrine. "We look forward to assessing further bavituximab's anti-cancer potential in our ongoing clinical trials, as well as in new combination therapy clinical studies we will be initiating later this year."

In this study, the anti-phosphatidylserine (anti-PS) monoclonal antibody 2aG4 (a mouse equivalent antibody to bavituximab) was administered to male mice that had been injected with common forms of hormone dependent and hormone independent tumor cells. Docetaxel and 2aG4 alone
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes

Post Your Comments:
(Date:11/25/2009)... Reportlinker.com announces that a...talogue: ,, Mammography Equipment - A Global ...r.com/p0164330/Mammography-Equipment---A-Global-Ma...reast cancer in industrialized as well as developi...h in the mammography market. Globally, escalating ...
(Date:11/25/2009)... 25 NuVasive, Inc. (Nasd...eveloping products for minimally disruptive surgic...it will host a conference call on Monday, November...nference call will focus on current issues relativ...will include comments from management followed by ...
(Date:11/25/2009)...rlands and JOHANNESBURG, November 25 /PRNewswire/ ...yxis Discovery announced today,that they have sign...h,companies, services. , Pyxis,s world cl...ertise,will be coupled with iThemba,s service divi...support to projects identified through Pyxis,inte...
Breaking Medicine Technology:Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3NuVasive Announces Conference Call and Webcast Regarding Reimbursement 4iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2Leading Womens Health Expert Offers Preventive Tips for Healthful Aging 56564 1Leading Womens Health Expert Offers Preventive Tips for Healthful Aging 56564 2Leading Womens Health Expert Offers Preventive Tips for Healthful Aging 56564 3Leading Womens Health Expert Offers Preventive Tips for Healthful Aging 56564 4China Kangtai Cactus Biotech to Present at the Rodman 26 Renshaw Annual Global Investment Conference in New York on September 11 2009 56560 1China Kangtai Cactus Biotech to Present at the Rodman 26 Renshaw Annual Global Investment Conference in New York on September 11 2009 56560 2China Kangtai Cactus Biotech to Present at the Rodman 26 Renshaw Annual Global Investment Conference in New York on September 11 2009 56560 3Obesity Driving Americas Healthcare to a Tipping Point 56556 1Obesity Driving Americas Healthcare to a Tipping Point 56556 2Obesity Driving Americas Healthcare to a Tipping Point 56556 3Obesity Driving Americas Healthcare to a Tipping Point 56556 4
...ained pain-free results compared to,sumatriptan, R... 03, 2007,/PRNewswire-FirstCall/ -- -- Findings fr... migraine sufferers demonstrated that,Trexima(TM) ... four,hours compared to placebo, and two through 2...tan or naproxen monotherapy. The,results were publ...
...ent data from,Synovate Healthcare’s European...cancer patients in the UK could become eligible,fo...tes in,patients. The treatment was the subject of ...he Lancet (12 February 2007). Lower,mortality rate...romotase inhibitor, Aromasin (exemestane), after 2...
Other Medicine Technology:Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data,Published in JAMA 2Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data,Published in JAMA 3Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data,Published in JAMA 4Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data,Published in JAMA 5Over 10,000 UK Breast Cancer Patients Could Become Eligible Within,the Next Year for a Breast Cancer Therapy Showing Increased,Survival Rates, Reveals Synovate Healthcare’s European,Oncology Monitor 2Over 10,000 UK Breast Cancer Patients Could Become Eligible Within,the Next Year for a Breast Cancer Therapy Showing Increased,Survival Rates, Reveals Synovate Healthcare’s European,Oncology Monitor 3
(Date:11/27/2009)...firm Replikins Ltd. today issued its latest bioche... shows that the lethality of the virus has dropped...s current outbreak in the spring of 2009 to restin... The H1N1 infectivity count, however, remains incr...ovember 27, 2009 -- Biotech firm Replikins Ltd., w...
(Date:11/27/2009)...rance, Nov. 27 Team Garmin-Slipstr...dedicated to ethical sporting and developing the n...ay that it will become Team Garmin-Transitions wit...nsor of the team. Transitions Optical is the world...ing the most advanced photochromic technology in t...
(Date:11/27/2009)...ed medical, economic burdens, study predicts , ...umber of people with diabetes in the United States...ew study predicts. , That would bring the total...ease, up from 23.7 million today. , , At the sam...will triple, the study also warns, rising from an ...
(Date:11/27/2009)...st manufacturers who use medical load cells at the...llars by bringing in technology partner Flintec ea...ro-active medical manufacturers are calling in Fli...ir projects, ensuring that progress will not be co...lly outdated technology. , ...
(Date:11/26/2009)... of Americans living with diabetes will nearly dou...million in 2034. Over the same period, spending on...lion to $336 billion, even with no increase in the...niversity of Chicago report in the December issue ...iabetes covered by Medicare will rise from 8.2 mil...
Breaking Medicine News(10 mins):Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3
...t should consider Medical Council of India seniori...s Association// for Social Equality' said today. ... Secretary, Dr G R Ravindranath, said according to...ent health services, the government should conside...
..., contrast-enhanced sonography compared with sonog...essment of blunt abdominal trauma.// Massimo ...objective of our study was to prospectively compar...s”. The study was conducted by the departmen...
...ied a novel gene that facilitates the spread of ma...//using a technique they say can speed the discove...ientists from Dana-Farber Cancer Institute, led by...nomas that have not spread. The protein made...
...hat physical inactivity due to lack of recreationa...the surrounding area make rural people obese.// ... the link between obesity and the environmental fa...es of a community that encourage physical activity...
...omyalgia (FM) experience significant pain, fatigue... misdiagnosed// or under treated as a normal part ...aren M. Schaefer, D.N.Sc., R.N., assistant profess... muscles and soft tissues of the body. Many suffer...
...y of Rochester Medical Centre say that the antipsy...de effects. //Clopazine is the most effective anti... last hope for many people. But there are long-ter...amberti, the lead author of the study. The...
Other Medicine News:Health News:New Tool Found to be Effective in Assessing Blunt Abdominal Trauma 2Health News:Researchers have Identified the Gene that Spreads Skin Cancer 2Health News:Environmental Factors Leads to Obesity in Rural Communities 2Health News:Fibromyalgia Increases Pain and Fatigue for Pregnant Women 2
Knolle-Shepard Lens Forceps
Buratto Insertion Forceps - Angled
Acrysof Insertion Forceps
Hydro Folding Forceps
Medicine Products: